The deal gives the Anglo-Swedish drugmaker complete control of Caelum's late-stage medicine for light chain (AL) amyloidosis, a potentially fatal disease that causes the rogue protein amyloid to ...

Almost four years after it was approved in Europe to treat the incurable rare disease systemic amyloid light-chain (AL) amyloidosis, Johnson & Johnson’s Darzalex has been given the go-ahead for ...

RIKEN researchers have demonstrated the protective effects of a specific genetic mutation against Alzheimer's disease in ...

These diseases include systemic amyloidoses in which deposits may occur in any part of the body, such as AL amyloidosis due to the accumulation of immunoglobulin light chain amyloid fibrils ...

Gantenerumab and other anti-amyloid drugs have been linked to a side ... More information: Bateman RJ, et al. Safety and efficacy of long-term gantenerumab treatment in dominantly inherited ...

[Courtesy of van Olst et al., Nature Medicine, 2025 ... RAB13, FAM107A, and other known amyloid response genes, including LAMP1, ITGAX, and APOC1; heat-shock proteins were turned down. Confocal ...

More information: Yuji Goto et al, Peristaltic pump-triggered amyloid formation suggests shear stresses are in vivo risks for amyloid nucleation, npj Biosensing (2025). DOI: 10.1038/s44328-025 ...

The risk for amyloid-related imaging abnormalities in early-stage Alzheimer’s disease is primarily driven by the ...

This study included 97 patients (57 had cardiac transthyretin amyloidosis, 20 had cardiac light chain amyloidosis, 3 had ApoA1 or ApoA4, 8 had systemic amyloidosis but no cardiac involvement, and 17 ...